For patients with metastatic pancreatic ductal adenocarcinoma, treatment is primarily directed at controlling systemic disease. Yet progression of the primary pancreatic tumor remains clinically important, even when cancer has already spread beyond the pancreas.
Local tumor growth can cause severe pain, biliary obstruction, gastrointestinal bleeding, impaired nutrition, and other complications that substantially affect quality of life. The question is whether carefully delivered local radiotherapy can control the pancreatic tumor without adding excessive toxicity to an already demanding treatment course.
A prospective observational study published in the World Journal of Gastroenterology suggests that five-fraction stereotactic magnetic resonance-guided adaptive radiotherapy may provide durable local control and meaningful pain relief in selected patients with metastatic pancreatic cancer.
The study, led by Mohamed A Schumann and colleagues, evaluated 24 patients treated at LMU University Hospital Munich. At 12 months, local control reached 76%, while 89% of patients who had pancreatic cancer-related pain reported improvement following treatment.
Title: “Five-fraction stereotactic magnetic resonance-guided adaptive radiotherapy targeting the primary tumor in metastatic pancreatic cancer”
Authors: Mohamed A Schumann, Aurélie Gaasch, Sandra Boyaci, Frederik Fuchs, Franziska Walter, Sebastian N Marschner, Chukwuka Eze, Christoph Benedikt Westphalen, Julian Walter Holch, Georg Beyer, Wolfgang G Kunz, Julia Mayerle, Maximilian Niyazi, Claus Belka, Stefanie Corradini, Paul Rogowski
Why the Primary Tumor Still Matters in Metastatic Disease
Systemic therapy remains the foundation of treatment for metastatic pancreatic ductal adenocarcinoma. Regimens such as FOLFIRINOX and gemcitabine with nab-paclitaxel can delay progression and extend survival, but outcomes remain limited.
At the same time, control of metastatic disease does not necessarily prevent complications from the primary pancreatic tumor.
Progressive disease within the pancreas may invade nearby nerves, blood vessels, the duodenum, stomach, or biliary structures. This can result in persistent pain, bleeding, jaundice, obstruction, and repeated interventions. Local progression therefore remains a major source of morbidity and may contribute to mortality, even in patients with distant metastases.
Stereotactic body radiotherapy offers a way to deliver concentrated radiation over a small number of treatment sessions. However, pancreatic tumors are particularly challenging targets because they move with respiration and lie close to highly radiosensitive organs, including the stomach, duodenum, and small bowel.
Magnetic resonance-guided radiotherapy was developed partly to address these limitations. The technology allows clinicians to visualize the tumor and surrounding anatomy immediately before each fraction, modify the treatment plan when necessary, and monitor tumor motion during radiation delivery.
A Prospective Study of Five-Fraction Treatment
The study included 24 consecutive patients with synchronous or metachronous metastatic pancreatic ductal adenocarcinoma treated between January 2020 and January 2025.
The median age was 65 years, with a range of 49 to 84 years. Most patients had preserved functional status: 92% had an Eastern Cooperative Oncology Group performance status of 0 or 1.
At the time of magnetic resonance-guided radiotherapy, 58% of patients had oligometastatic disease, defined as five or fewer metastases, while 42% had more extensive metastatic disease. Three-quarters had metastases confined to a single organ.
The liver was the most common metastatic site, accounting for 50% of cases. Lung-only metastases were present in 17%, non-regional lymph node metastases in 8%, peritoneal carcinomatosis in 17%, and multi-organ involvement in 8%.
Most patients had already received systemic therapy. Twenty-two of the 24 patients underwent chemotherapy before radiotherapy, including 16 treated with modified or standard FOLFIRINOX and four treated with gemcitabine plus nab-paclitaxel.
The median duration of chemotherapy before radiotherapy was seven months, corresponding to a median of 12 cycles.
Four Clinical Reasons for Delivering Local Radiotherapy
Patients received magnetic resonance-guided radiotherapy for several different clinical indications, reflecting the range of situations encountered in routine practice.
Nine patients, representing 38% of the cohort, received radiotherapy as consolidative treatment after achieving at least stable disease with chemotherapy.
Five patients, or 21%, were treated because the primary pancreatic tumor was progressing while metastatic sites remained controlled.
Three patients, or 13%, received treatment to the pancreatic primary as part of a broader strategy targeting all visible sites of oligometastatic disease.
The remaining seven patients, representing 29%, received radiotherapy with palliative intent because of pain, progressive disease, or an inability to tolerate further chemotherapy.
This distinction proved important when survival outcomes were analyzed.
Daily Adaptation Around a Difficult Anatomical Target
All patients were treated using a 0.35-T magnetic resonance-linear accelerator.
Radiotherapy was delivered in five fractions, with a total dose ranging from 33 Gy to 40 Gy. Thirteen patients received 33 Gy, while 11 received 33 Gy to an elective target volume with a simultaneous integrated boost to 40 Gy directed at the visible tumor.
Before each fraction, a new magnetic resonance scan was obtained. The pancreas and adjacent organs at risk were re-contoured according to the patient’s anatomy on that particular day.
The treatment plan was adapted when necessary to maintain target coverage while respecting dose limits for the stomach, duodenum, and small bowel. Continuous magnetic resonance imaging was also used during treatment, with automatic beam interruption if tumor motion exceeded the predefined treatment boundaries.
This daily adaptive approach is especially relevant in pancreatic cancer, where small changes in bowel filling or organ position may substantially alter the relationship between the tumor and nearby gastrointestinal structures.
Local Control Remained High at Two Years
The study’s primary endpoint was local control of the treated pancreatic tumor.
At 12 months, the local control rate was 76%. At 24 months, it remained 67%.
Six patients experienced local failure. One developed an isolated local recurrence, while five experienced locoregional recurrence alongside progression in the organ that had originally contained metastatic disease.
The median time to distant progression was three months, highlighting the continued systemic nature of metastatic pancreatic cancer. Sixteen patients experienced progression at pre-existing metastatic sites, while six developed metastases in new locations despite maintaining control of the treated pancreatic tumor.
These findings illustrate both the potential and the limitation of local treatment. Magnetic resonance-guided radiotherapy provided durable control within the pancreas for many patients, but it did not eliminate the risk of rapid progression elsewhere in the body.
Pain Improved in Nearly Nine of Ten Symptomatic Patients
Nine patients reported pancreatic cancer-related pain before radiotherapy.
At three months, eight of these nine patients, or 89%, experienced improvement. Three reported complete resolution of pain and were able to discontinue analgesic treatment.
Five patients, representing 56% of those with baseline pain, reduced their opioid use.
Pain palliation is an important outcome in pancreatic cancer, where local invasion of neural structures can cause severe and difficult-to-control symptoms. The observed improvement suggests that local tumor control may translate into clinically meaningful relief for appropriately selected patients.
However, pain was assessed through retrospective review of routine clinical documentation rather than standardized prospective quality-of-life instruments. The authors therefore emphasized that the symptom findings should be interpreted with appropriate caution.
Survival Was Closely Linked to Patient Selection
Median overall survival was 13 months from the completion of magnetic resonance-guided radiotherapy. The one-year overall survival rate was 49%.
Measured from the diagnosis of metastatic disease, median overall survival was 20 months.
Survival differed considerably according to the clinical setting in which radiotherapy was delivered.
Patients treated with consolidative intent after stable metastatic disease had a median overall survival of 13.2 months following radiotherapy. Those treated for isolated progression of the primary tumor had a median overall survival of 18.1 months.
By comparison, patients receiving radiotherapy primarily for palliation, chemotherapy intolerance, or polyprogressive disease had a median overall survival of five months.
The difference between the consolidative and isolated primary-progression groups was not statistically significant. However, both groups had significantly better survival than the palliative cohort.
These results suggest that the favorable overall outcomes were largely driven by patients whose metastatic disease was controlled and whose treatment was delivered as part of a planned multimodal strategy, rather than by patients with widespread active progression.
Single-Organ Disease and Stable Metastases Identified a More Favorable Group
Exploratory subgroup analyses identified several characteristics associated with longer survival.
Patients whose metastases were confined to a single organ had a median overall survival of 14 months after radiotherapy, compared with five months among those with multi-organ disease or peritoneal carcinomatosis.
Patients with an ECOG performance status of 0 achieved a median overall survival of 15 months, compared with 10 months among those with an ECOG status of 1 or 2.
Baseline carbohydrate antigen 19-9 levels also appeared prognostic. Patients with CA19-9 below 500 U/mL had a median overall survival of 23 months, compared with 11 months among those with levels of 500 U/mL or higher.
Perhaps most importantly, patients whose distant metastatic sites were stable at the time of radiotherapy had a median overall survival of 14 months. Those with uncontrolled metastatic disease had a median survival of five months.
No significant survival association was identified for the number of metastatic lesions, treatment with a 40 Gy simultaneous integrated boost, the use of metastasis-directed therapy, the number of previous systemic therapy lines, or the response of the primary tumor to induction chemotherapy.
The study was not powered to establish definitive predictive factors, and the subgroup findings remain exploratory. Nevertheless, they reinforce the importance of disease biology, systemic control, functional status, and metastatic distribution when considering local treatment.
High-Grade Toxicity Was Uncommon but Clinically Relevant
Two patients experienced acute grade 3 gastrointestinal events that were considered possibly related to radiotherapy.
One patient receiving anticoagulation developed gastrointestinal bleeding 66 days after treatment. Endoscopy demonstrated circumferential ulcerated tumor infiltration of the duodenum with diffuse bleeding. Radiation doses remained within the institution’s predefined duodenal constraints, and the investigators considered a mixed tumor- and treatment-related cause most likely.
A second patient developed common bile duct obstruction 63 days after radiotherapy because of migration of a biliary stent. The stent was removed and replaced endoscopically. Although a direct effect of radiotherapy on stent displacement was considered unlikely, a contribution to worsening bile duct stenosis could not be completely excluded.
No late grade 3 toxicities and no grade 4 or 5 adverse events were observed.
The overall safety profile was therefore considered favorable, although the cases also demonstrate the difficulty of distinguishing treatment toxicity from complications caused by locally invasive pancreatic cancer.
Dose Escalation Did Not Produce a Clear Advantage
The study used total doses of either 33 Gy or 40 Gy in five fractions.
No significant improvement in local control or overall survival was observed with the 40 Gy simultaneous integrated boost. However, the small sample size limits any conclusion regarding the comparative effectiveness of the two dose levels.
Both regimens were also below the 50 Gy in five fractions frequently used in modern studies of locally advanced pancreatic cancer.
Whether a higher biologically effective dose can further improve local control in metastatic disease remains uncertain. Any potential benefit must be balanced against gastrointestinal toxicity, treatment burden, competing distant progression, and the overall goals of care.
The authors noted that advanced motion management and adaptive planning are particularly important when dose escalation is being considered. For centers without magnetic resonance-guided systems, conventionally delivered or computed tomography-guided adaptive stereotactic radiotherapy may remain feasible at doses of up to 40 Gy in appropriately selected patients.
Promising Findings, but Not a New Standard
This study provides prospective evidence supporting the feasibility of magnetic resonance-guided radiotherapy to the primary tumor in metastatic pancreatic cancer.
However, several limitations prevent broad conclusions.
The analysis involved only 24 patients from a single institution. The cohort was heterogeneous in terms of metastatic burden, treatment indication, systemic therapy, previous surgery, and use of metastasis-directed treatment.
There was also no control group receiving systemic therapy alone. Comparisons with historical chemotherapy outcomes are therefore vulnerable to selection bias, particularly because patients chosen for consolidative radiotherapy were more likely to have stable disease and favorable functional status.
The rapid median time to distant progression further emphasizes that radiotherapy cannot replace effective systemic treatment in metastatic pancreatic cancer.
Instead, the findings support its consideration as an additional local strategy for carefully selected patients, particularly those with controlled metastatic disease, good performance status, limited organ involvement, and a persistent risk of morbidity from the primary pancreatic tumor.
Defining the Right Patient for Local Treatment
The central question is no longer simply whether the pancreatic primary can be treated safely in metastatic disease. The more clinically relevant question is which patients are most likely to benefit.
In this study, outcomes were most favorable among patients with stable distant disease, single-organ metastases, lower CA19-9 levels, and excellent performance status. Patients treated for consolidation or isolated progression of the pancreatic primary also lived substantially longer than those treated during widespread progression or chemotherapy intolerance.
The results do not establish magnetic resonance-guided radiotherapy as a routine treatment for metastatic pancreatic cancer. They do, however, strengthen the rationale for prospective evaluation of primary-directed radiotherapy within carefully designed multimodal strategies.
For selected patients, five treatment fractions may offer more than temporary palliation. They may provide durable control of a clinically consequential primary tumor, reduce pain, and help prevent some of the complications that make metastatic pancreatic cancer particularly difficult to manage.
Written by Nare Hovhannisyan, MD
Discover more articles like this on OncoDaily.